# Plain Language Summary: Give Kids a Chance Act of 2022

This bill is about making sure that cancer drugs being developed for adults are also tested in children to see if they might work for pediatric cancers. Right now, when pharmaceutical companies develop new cancer treatments, they often focus on adult patients first. This bill requires the FDA to push companies to study how these drugs work in children, particularly when the drugs use "molecularly targeted" approaches—meaning they're designed to attack specific genetic mutations that drive cancer growth.

The bill specifically addresses two situations. First, it allows the FDA to require testing of new drug combinations in children if each individual drug in the combination has already been approved to treat adult cancer. Second, it gives the FDA authority to require companies to conduct early laboratory studies (preclinical studies) on cancer drugs to determine whether the drug's target is relevant to childhood cancers. These preclinical studies would happen before or early in human testing, helping researchers understand if a drug has potential to help kids before investing in full pediatric trials.

The practical effect is that children with cancer will have better access to cutting-edge treatments that are being developed. Instead of waiting years for adult drugs to eventually be studied in kids—if they ever are—companies will need to include pediatric research as part of their development process. This doesn't mean every cancer drug will automatically be tested in children, but the FDA now has clearer authority to require it when scientifically appropriate. The bill gives companies three years from when it becomes law to comply with these new requirements for drugs they're developing.

Give Kids a Chance Act of 2022

Butterfield, G. K.

Give Kids a Chance Act of 2022 This bill authorizes the Food and Drug Administration (FDA) to take various actions regarding pediatric cancer treatments, such as requiring pediatric cancer trials involving a combination of drugs when an applicant seeks market approval for a new drug (or biological product).